Evidence map›Paper›PMID 38365175›Full record

ReviewChest2024

An Update on Patient-Reported Outcomes in Asthma.

Tianshi David Wu, Zuzana Diamant, Nicola A Hanania

Abstract readReview
In one paragraph

Review in Chest, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Patient-reported treatment outcomes in ME/CFS and long COVID.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Tianshi David WuSection of Pulmonary, Critical Care, and Sleep Medicine, Baylor College of Medicine, Houston TX; Center for Innovations in Quality, Effectiveness, and Safety, Michael E. DeBakey VA Medical Center, Houston TX. Electronic address: david.wu@bcm.edu.
Zuzana DiamantDepartment of Clinical Pharmacy & Pharmacology, University Medical Center Groningen, Groningen, The Netherlands; Department of Respiratory Medicine & Allergology, Skåne University Hospital, Lund, Sweden.
Nicola A HananiaSection of Pulmonary, Critical Care, and Sleep Medicine, Baylor College of Medicine, Houston TX.

Funding

Insulin Resistance, Pre-Diabetes, and Diabetes in Obesity-Associated AsthmaK23HL151669 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI WU, TIANSHI DAVID · 2021 to 2025
$1.0M
Metformin IN Asthma for overweight and obese individuals (MINA)R34HL166438 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI MCCORMACK, MEREDITH C, WU, TIANSHI DAVID · 2023 to 2025
$758k
NHLBI NIH HHS K23 HL151669NHLBI NIH HHS R34 HL166438
6 · The paper itself

Abstract

topic importancePatient-reported outcomes (PROs) are information provided by patients on their condition, function, well-being, or experience. Instruments to quantify PROs, called patient-reported outcome measures (PROMs), allow standardized assessment of a unique dimension of health that cannot be measured physically. Herein, we discuss how to appraise PROMs critically and provide an update on their use in asthma clinical practice and research. REVIEW

findingsAsthma-specific PROMs have been developed to measure a wide array of disease characteristics, including symptoms, medication use, exacerbations, and impairments to emotional and physical function. Some PROMs also include spirometry or expand questions to overlap with rhinitis symptoms. Use of PROMs to understand asthma control is included in management guidelines, yet real-world evidence of their effectiveness in improving asthma care remains limited. These instruments may be less accurate in characterizing patients with poorly controlled asthma and have modest correlation with exacerbation risk. Two new PROMs are highlighted, the Asthma Impairment and Risk Questionnaire as an instrument to assess asthma control that incorporates domains related to exacerbation risk and impairment, and the CompEx as a composite of daily diary reporting combined with exacerbation events as an early efficacy signal for interventional trials. SUMMARY: PROMs are fundamental to asthma assessment. Novel instruments may improve the detection of patients at risk for poor outcomes and shorten the drug discovery pipeline. However, urgent research is needed to understand their practical utility in clinical settings.

Indexed as

AsthmaPatient Reported Outcome MeasuresHumansQuality of Lifeasthmanarrative reviewoutcomesPROPROMvalidity

Identifiers

PMID38365175
PMCPMC13170135

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.